Process Development For CGT: How Soon Is Too Soon? (Houston)

Every cell and gene therapy program eventually faces the same timing question: how early should process development begin, and what does starting too soon actually cost? Recorded at the inaugural event for the expanded Process and Analytical Development Laboratories at Lonza Houston, this panel brings together voices from consulting, biotech, and large-scale development to discuss where commercial readiness fits into the development timeline. Anthony Davies, CEO of Dark Horse Consulting, chairs the discussion with Brian Price, co-founder of Neucore Bio; Heikki Jouttijarvi, SVP and Head of Tech Ops at Adverum Biotechnologies, Inc.; Maxwell De Long, Director and Senior Principal, Individualized Medicines at Genentech; and Behnam Ahmadian Baghbaderani, Global Head of CGT Process Development. Watch the session to hear how these panelists approach the question.